<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00905762</url>
  </required_header>
  <id_info>
    <org_study_id>608</org_study_id>
    <nct_id>NCT00905762</nct_id>
  </id_info>
  <brief_title>Concentration of Besifloxacin, Gatifloxacin, and Moxifloxacin in Human Conjunctiva After Topical Instillation</brief_title>
  <official_title>A Single-Center, Randomized, Masked Study Comparing the Concentration of Besifloxacin, Gatifloxacin, and Moxifloxacin in Human Conjunctiva After a Single Topical Instillation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bausch &amp; Lomb Incorporated</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bausch &amp; Lomb Incorporated</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the concentration of besifloxacin compared to
      gatifloxacin and moxifloxacin in human conjunctival tissue, following a single drop of the
      drug instilled topically into the study eye. Conjunctival biopsies will be performed at
      specified time points, followed by the use of loteprednol etabonate/tobramycin ophthalmic
      suspension four times a day for 5 days.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2009</start_date>
  <completion_date type="Actual">April 2009</completion_date>
  <primary_completion_date type="Actual">April 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Concentration of besifloxacin, gatifloxacin or moxifloxacin in conjunctival tissue.</measure>
    <time_frame>Biopsies collected at specified time points from 15 minutes to 24 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Visual acuity</measure>
    <time_frame>Day -14 through Day 6(+/-1)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Slit Lamp Biomicroscopy</measure>
    <time_frame>Day -14 through Day 6 (+/-)</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">119</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Besifloxacin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Besifloxacin one drop instilled into study eye.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gatifloxacin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Gatifloxacin one drop instilled into study eye.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Moxifloxacin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Moxifloxacin one drop instilled into study eye.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gatifloxacin</intervention_name>
    <description>Gatifloxacin 0.3% one drop instilled into study eye at visit 2.</description>
    <arm_group_label>Gatifloxacin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Moxifloxacin</intervention_name>
    <description>Moxifloxacin 0.5% one drop instilled into study eye at visit 2.</description>
    <arm_group_label>Moxifloxacin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Besifloxacin</intervention_name>
    <description>Besifloxacin 0.6% one drop instilled into study eye at visit 2.</description>
    <arm_group_label>Besifloxacin</arm_group_label>
    <other_name>Besivance</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Willing to avoid all disallowed medications for the appropriate washout periods.

          -  Have a best corrected visual acuity of 0.60 logMAR or better in each eye as measured
             using an ETDRS chart.

        Exclusion Criteria:

          -  Have a known allergy and/or sensitivity to the test articles or its components or any
             therapy associated with the trial.

          -  Monocular.

          -  Have previously participated in a conjunctival biopsy study.

          -  Be currently enrolled in an investigational drug or device study or have uses of an
             investigational drug or device within 30 days of entry into this study.

          -  have a condition or is in a situation which the investigator feels may put the subject
             at significant risk, may confound the study results, or may interfere significantly
             with the subject's participation in the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Timothy Comstock, OD</last_name>
    <role>Study Director</role>
    <affiliation>Bausch &amp; Lomb Incorporated</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bausch &amp; Lomb Incorporated</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 3, 2009</study_first_submitted>
  <study_first_submitted_qc>May 20, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 21, 2009</study_first_posted>
  <last_update_submitted>December 7, 2011</last_update_submitted>
  <last_update_submitted_qc>December 7, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 9, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pharmacokinetics</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Moxifloxacin</mesh_term>
    <mesh_term>Fluoroquinolones</mesh_term>
    <mesh_term>Gatifloxacin</mesh_term>
    <mesh_term>7-(3-aminohexahydro-1H-azepin-1-yl)-8-chloro-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid</mesh_term>
    <mesh_term>Norgestimate, ethinyl estradiol drug combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

